Rare Cancer News & Clinical Trials » Trial

Trial - Angiosarcoma (25 unread)

Agnostic Therapy in Rare Solid Tumors

Posted: October 14th, 2024, 11:00pm UTC

Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
Interventions: Drug: Nivolumab
Sponsors: Instituto do Cancer do Estado de SÃ£o Paulo; Financiadora de Estudos e Projetos
Recruiting
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Posted: August 7th, 2024, 11:00pm UTC

Conditions: Hepatocholangiocarcinoma; Fibrolamellar Carcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Hepatic Neuroendocrine Carcinoma; Hepatic Carcinosarcomas; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Cholangiocarcinoma
Sponsors: Federation Francophone de Cancerologie Digestive; SociÃ©tÃ© Nationale FranÃ§aise de GastroentÃ©rologie
Recruiting
Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE

Posted: August 2nd, 2024, 11:00pm UTC

Conditions: Cancer; Cystic Carcinomas, Adenoid; Soft-tissue Sarcomas; Rhabdomyosarcoma Pleomorphic; Sarcoma,Soft Tissue; Osteosarcomas; Chondrosarcoma, Grade 3; Chordoma; Angiosarcomas
Interventions: Other: Questionnaire
Sponsors: Hospices Civils de Lyon; Centre FranÃ§ois Baclesse, Centre de lutte contre le cancer (CLCC)
Not yet recruiting
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

Posted: July 30th, 2024, 11:00pm UTC

Conditions: Adult Pleomorphic Rhabdomyosarcoma; AJCC Grade 2 Sarcoma; AJCC Grade 3 Sarcoma; Alveolar Soft Part Sarcoma; Angiosarcoma; Clear Cell Sarcoma of Soft Tissue; Dedifferentiated Liposarcoma; Extraskeletal Ewing Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Fibrosarcoma; Fibrosarcomatous Dermatofibrosarcoma Protuberans; Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Myxofibrosarcoma; Pleomorphic Liposarcoma; Round Cell Sarcoma With EWSR1-non-ETS Fusion; Sarcoma; Soft Tissue Sarcoma; Soft Tissue Sarcoma of the Trunk and Extremities; Spindle Cell Sarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Synovial Sarcoma; Undifferentiated Pleomorphic Sarcoma
Interventions: Procedure: Biopsy; Procedure: Chest Computed Tomography; Procedure: Chest Radiography; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Not yet recruiting
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

Posted: April 19th, 2024, 11:00pm UTC

Conditions: Angiosarcoma
Interventions: Other: Observational
Sponsors: Italian Sarcoma Group
Recruiting
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Posted: February 26th, 2024, 1:00am UTC

Conditions: Leiomyosarcoma; Liposarcoma; Synovial Sarcoma; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma; Epithelioid Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Fibrosarcoma; Pleomorphic Rhabdomyosarcoma; Endometrial Stromal Sarcoma; Desmoplastic Small Round Cell Tumor
Interventions: Biological: MASCT-I; Drug: Doxorubicin; Drug: Ifosfamide
Sponsors: HRYZ Biotech Co.
Not yet recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Posted: May 15th, 2023, 11:00pm UTC

Conditions: Cutaneous Squamous Cell Carcinoma; SCC - Squamous Cell Carcinoma; Basal Cell Carcinoma; BCC; BCC - Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Sebaceous Carcinoma; Extramammary Paget Disease; Kaposi Sarcoma; Head and Neck Squamous Cell Carcinoma; HNSCC; Adnexal Carcinoma; Angiosarcoma; Cutaneous Neoplasm; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Solid Tumor
Interventions: Biological: MQ719; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center
Active, not recruiting
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Posted: April 24th, 2023, 11:00pm UTC

Conditions: Solid Tumor
Interventions: Drug: OMX-0407
Sponsors: iOmx Therapeutics AG
Recruiting
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Posted: April 5th, 2023, 11:00pm UTC

Conditions: Angiosarcoma
Interventions: Drug: Paclitaxel; Biological: mRNA plus Lysate-loaded Dendritic Cell Vaccine; Drug: PEGYLATED-INTERFERON ALPHA-2A; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; Cancer Cures 4 Kids
Recruiting
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Posted: August 30th, 2021, 11:00pm UTC

Conditions: Locally Advanced Angiosarcoma; Metastatic Angiosarcoma; Recurrent Angiosarcoma
Interventions: Other: Quality-of-Life Assessment; Biological: Sintilimab
Sponsors: M.D. Anderson Cancer Center
Active, not recruiting
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Posted: August 9th, 2021, 11:00pm UTC

Conditions: Leiomyosarcoma
Interventions: Drug: Ontorpacept (TTI-621); Drug: Doxorubicin
Sponsors: Pfizer
Terminated
Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Posted: April 26th, 2021, 11:00pm UTC

Conditions: Angiosarcoma Metastatic
Interventions: Drug: Abraxane combined with liposomal doxorubicin
Sponsors: Sun Yat-sen University
Recruiting
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Posted: March 5th, 2021, 1:00am UTC

Conditions: Advanced Sarcoma
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Parker Institute for Cancer Immunotherapy
Active, not recruiting
$Permalink for 'Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma'$
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Posted: December 16th, 2020, 1:00am UTC

Conditions: Metastatic Angiosarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Osteosarcoma; Recurrent Angiosarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Osteosarcoma; Refractory Dedifferentiated Liposarcoma; Refractory Osteosarcoma
Interventions: Biological: Durvalumab; Biological: Oleclumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Posted: August 13th, 2019, 11:00pm UTC

Conditions: Bone Sarcoma; Osteosarcoma; Ewing Sarcoma; Chondrosarcoma; Undifferentiated Pleomorphic Sarcoma; Leiomyosarcoma; Angiosarcoma
Interventions: Drug: Treatment by Regorafenib; Drug: Treatment by Placebo
Sponsors: Centre Leon Berard
Recruiting
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

Posted: April 19th, 2019, 11:00pm UTC

Conditions: Cutaneous Angiosarcoma
Interventions: Drug: Paclitaxel; Radiation: Radiation therapy; Procedure: Research blood draw
Sponsors: Washington University School of Medicine
Recruiting
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Posted: March 1st, 2019, 1:00am UTC

Conditions: Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases; Endometrial Cancer; Fibrolamellar Carcinoma; Non-small-cell Lung Cancer; Ovarian Cancer; Prostate Cancer
Interventions: Drug: Botensilimab; Drug: Balstilimab
Sponsors: Agenus Inc.
Recruiting
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Posted: November 14th, 2018, 1:00am UTC

Conditions: Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor
Sponsors: National Cancer Institute (NCI)
Recruiting
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Posted: January 29th, 2018, 1:00am UTC

Conditions: Sarcoma
Interventions: Drug: Epacadostat; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Incyte Corporation; Merck Sharp & Dohme LLC; M.D. Anderson Cancer Center
Active, not recruiting
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Posted: September 13th, 2017, 11:00pm UTC

Conditions: SARCOMA
Interventions: Drug: NKTR-214; Drug: Nivolumab
Sponsors: Memorial Sloan Kettering Cancer Center; M.D. Anderson Cancer Center; Stanford University; Rockefeller University
Active, not recruiting
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Posted: September 11th, 2017, 11:00pm UTC

Conditions: Soft Tissue Sarcoma; Bone Sarcoma
Interventions: Drug: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]; Drug: Nivolumab 100 MG/10 ML [Opdivo]; Drug: Epirubicin; Drug: Ifosfamide; Drug: Doxorubicin; Drug: Dacarbazine; Drug: Cisplatin; Drug: Methotrexate
Sponsors: Grupo Espanol de Investigacion en Sarcomas
Completed
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 11:00pm UTC

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Posted: June 28th, 2016, 11:00pm UTC

Conditions: Advanced and/or Metastatic Sarcoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: M.D. Anderson Cancer Center; MedImmune LLC
Completed
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Posted: January 5th, 2010, 1:00am UTC

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer
Interventions: Drug: Standard Therapy; Drug: AMG 386 with or without Trastuzumab; Drug: AMG 479 (Ganitumab) plus Metformin; Drug: MK-2206 with or without Trastuzumab; Drug: AMG 386 and Trastuzumab; Drug: T-DM1 and Pertuzumab; Drug: Pertuzumab and Trastuzumab; Drug: Ganetespib; Drug: ABT-888; Drug: Neratinib; Drug: PLX3397; Drug: Pembrolizumab - 4 cycle; Drug: Talazoparib plus Irinotecan; Drug: Patritumab and Trastuzumab; Drug: Pembrolizumab - 8 cycle; Drug: SGN-LIV1A; Drug: Durvalumab plus Olaparib; Drug: SD-101 + Pembrolizumab; Drug: Tucatinib plus trastuzumab and pertuzumab; Drug: Cemiplimab; Drug: Cemiplimab plus REGN3767; Drug: Trilaciclib with or without trastuzumab + pertuzumab; Drug: SYD985 ([vic-]trastuzumab duocarmazine); Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab; Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab; Drug: Amcenestrant; Drug: Amcenestrant + Abemaciclib; Drug: Amcenestrant + Letrozole; Drug: ARX788; Drug: ARX788 + Cemiplimab; Drug: VV1 + Cemiplimab; Drug: Datopotamab deruxtecan; Drug: Datopotamab deruxtecan + Durvalumab; Drug: Zanidatamab; Drug: Lasofoxifene; Drug: Z-endoxifen; Drug: ARV-471; Drug: ARV-471 + Letrozole
Sponsors: QuantumLeap Healthcare Collaborative
Recruiting
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

Posted: February 12th, 2009, 1:00am UTC

Conditions: Dermatologic Diseases
Interventions: Other: skin tissue sample
Sponsors: University of California, Irvine
Recruiting

← PubMed - Angiosarcoma Google - Appendix Cancer →

Rare Cancer News & Clinical Trials » Trial - Angiosarcoma

Feeds

Trial - Angiosarcoma (25 unread)

Posted: October 14th, 2024, 11:00pm UTC

Posted: August 7th, 2024, 11:00pm UTC

Posted: August 2nd, 2024, 11:00pm UTC

Posted: July 30th, 2024, 11:00pm UTC

Posted: April 19th, 2024, 11:00pm UTC

Posted: February 26th, 2024, 1:00am UTC

Posted: May 15th, 2023, 11:00pm UTC

Posted: April 24th, 2023, 11:00pm UTC

Posted: April 5th, 2023, 11:00pm UTC

Posted: August 30th, 2021, 11:00pm UTC

Posted: August 9th, 2021, 11:00pm UTC

Posted: April 26th, 2021, 11:00pm UTC

Posted: March 5th, 2021, 1:00am UTC

Posted: December 16th, 2020, 1:00am UTC

Posted: August 13th, 2019, 11:00pm UTC

Posted: April 19th, 2019, 11:00pm UTC

Posted: March 1st, 2019, 1:00am UTC

Posted: November 14th, 2018, 1:00am UTC

Posted: January 29th, 2018, 1:00am UTC

Posted: September 13th, 2017, 11:00pm UTC

Posted: September 11th, 2017, 11:00pm UTC

Posted: July 15th, 2016, 11:00pm UTC

Posted: June 28th, 2016, 11:00pm UTC

Posted: January 5th, 2010, 1:00am UTC

Posted: February 12th, 2009, 1:00am UTC